Influenza as an issue on the agenda of policy makers and government representatives. What can we do? What do we need?
- PMID: 17167888
- DOI: 10.1016/j.vaccine.2006.06.068
Influenza as an issue on the agenda of policy makers and government representatives. What can we do? What do we need?
Abstract
Influenza vaccinations and antiviral drugs are the foundation of epidemic and pandemic preparedness, but only close collaboration between public health authorities and industry can achieve the necessary production levels and ensure the smooth distribution necessary to protect European citizens from this public health scourge. To focus the minds of all public health stakeholders, ESWI has translated these simple facts into clear achievable goals: it recommends that EU governments vaccinate one-third of their populations by 2010 and stockpile antiviral drugs for 20% of their citizens while promoting public-private partnerships. The scientific justification behind this objective is easily understood namely that while the annual flu shot protects against three viral strains,the pandemic vaccine will focus on only the one highly lethal virus. As a result if countries succeed in meeting the target to vaccine one-third of the EU-25 population with a trivalent vaccine, sufficient monovalent pandemic vaccine could be produced to vaccinate almost the entire EU-25 population at least once. Achieving these objectives would go far to containing the pandemic and ensuring necessary treatment to avoid needless deaths and social and economic disruption. It would also signal that influenza preparedness had become part of the European mindset. Relying on the technique of force-field analysis organised by professional facilitators the session asked government representatives and policy makers to identify existing factors that either provide support for the objectives or hinder progress.
Similar articles
-
Pandemic planning in Canada.Eur J Epidemiol. 1994 Aug;10(4):503-5. doi: 10.1007/BF01719688. Eur J Epidemiol. 1994. PMID: 7843368
-
Modeling pandemic preparedness scenarios: health economic implications of enhanced pandemic vaccine supply.Virus Res. 2004 Jul;103(1-2):9-15. doi: 10.1016/j.virusres.2004.02.006. Virus Res. 2004. PMID: 15163482
-
Vaccination for pandemic influenza: a six point agenda for interpandemic years.Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S74-7. doi: 10.1097/01.inf.0000108195.12141.cc. Pediatr Infect Dis J. 2004. PMID: 14730273 Review.
-
Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy.Vaccine. 2005 Dec 30;23(50):5732-42. doi: 10.1016/j.vaccine.2005.10.011. Epub 2005 Oct 18. Vaccine. 2005. PMID: 16271423 Review.
-
The health care response to pandemic influenza.Ann Intern Med. 2006 Jul 18;145(2):135-7. doi: 10.7326/0003-4819-145-2-200607180-00131. Epub 2006 Jun 26. Ann Intern Med. 2006. PMID: 16801625
Cited by
-
Antiviral prophylaxis and isolation for the control of pandemic influenza.Int J Environ Res Public Health. 2014 Jul 31;11(8):7690-712. doi: 10.3390/ijerph110807690. Int J Environ Res Public Health. 2014. PMID: 25089775 Free PMC article.
-
Estimating antiviral effectiveness against pandemic influenza using household data.J R Soc Interface. 2009 Aug 6;6(37):695-703. doi: 10.1098/rsif.2008.0404. Epub 2008 Dec 5. J R Soc Interface. 2009. PMID: 19064345 Free PMC article.
-
Can antiviral drugs contain pandemic influenza transmission?PLoS One. 2011 Mar 28;6(3):e17764. doi: 10.1371/journal.pone.0017764. PLoS One. 2011. PMID: 21464934 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials